A patient’s hopes need not fit into the word “approved.” FDA’s March 13, 2017 ribociclib decision covered postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, using an aromatase inhibitor alongside it as initial endocrine-based therapy. In this March 16 retrospective, that defined permission begins the ethical discussion; it does not decide what every eligible patient should value. [209092Orig1s000ltr]

The March 2017 label described a randomized comparison of ribociclib plus letrozole against placebo plus letrozole. Its interim result concerned progression-free survival, while overall-survival data remained immature. Presenting that finding as a promise of cure or established longer life would replace uncertainty with reassurance the evidence could not supply. Respect for agency starts with naming the question the study actually addressed. [209092s000lbl]

The practical side deserved equally candid language. The label called for ECGs and electrolyte, liver-function and blood-count monitoring, including additional checks as clinically indicated. FDA also required future research on alternative dosing intended to reduce QT risk without compromising efficacy. Neither the monitoring instructions nor that research obligation guaranteed a safer personal outcome. They belong in the conversation alongside potential disease-control benefit. [209092Orig1s000ltr][209092s000lbl]

From an interfaith and nonreligious ethical perspective, the proposed response is listening rather than prescribing a shared moral answer. A patient could be invited to discuss what uncertainty and repeated monitoring mean in her own life, without supporters deciding for her or treating caution as a failure of hope. That is an editorial principle, not a documented religious consensus or study finding. This historical account offers no present-day treatment recommendation. [209092Orig1s000ltr][209092s000lbl]

Source documents

  1. NDA 209092: KISQALI approval letterhttps://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/209092Orig1s000ltr.pdf
  2. KISQALI (ribociclib) initial US prescribing informationhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209092s000lbl.pdf